4.7 Article

LncRNA LNC-565686 Promotes Proliferation of Prostate Cancer by Inhibiting Apoptosis through Stabilizing SND1

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Cell Biology

Targeting PI3K/Akt signaling in prostate cancer therapy

Mehrdad Hashemi et al.

Summary: This review highlights the role of the PI3K/Akt signaling pathway in the progression of prostate cancer, including its involvement in cell survival, apoptosis, cell cycle, proliferation, metastasis, drug resistance, and radiotherapy sensitivity.

JOURNAL OF CELL COMMUNICATION AND SIGNALING (2023)

Article Immunology

Circular RNA METTL9 contributes to neuroinflammation following traumatic brain injury by complexing with astrocytic SND1

Chunling Huang et al.

Summary: The expression level of circular RNA (circRNA) is upregulated in traumatic brain injury (TBI), which may contribute to neurodegenerative diseases. The circRNA METTL9 is identified as an important molecule that is upregulated after TBI and is involved in the pathological processes of TBI by regulating neuronal apoptosis and loss of function.

JOURNAL OF NEUROINFLAMMATION (2023)

Article Oncology

Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance

Ruchi Ghildiyal et al.

Summary: This study identifies a lncRNA called NXTAR that can epigenetically downregulate AR/AR-V7 expression, providing a therapeutic strategy to reinstate NXTAR expression for treating recurrent CRPC.

CANCER RESEARCH (2022)

Article Oncology

Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism

Liang Chen et al.

Summary: Our study revealed the interaction between circ_0004087 and the mitosis error correction mechanism, showing that circ_0004087 can stimulate the expression of BUB1 through SND1 and MYB, leading to enhanced mitotic accuracy of PCa cells. Furthermore, circ_0004087 was found to confer DTX resistance in PCa cells, suggesting its potential as a prognostic biomarker and therapeutic target in DTX-resistant PCa patients.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Oncology

Mitochondrion-Localized SND1 Promotes Mitophagy and Liver Cancer Progression Through PGAM5

Shiwei Liang et al.

Summary: This study reveals that SND1 is localized to mitochondria and promotes PGAM5-mediated mitophagy, playing a crucial role in regulating cell proliferation and tumor growth in liver cancer. Aberrant expression of SND1 and PGAM5 is associated with poor outcomes in hepatocellular carcinoma patients.

FRONTIERS IN ONCOLOGY (2022)

Review Oncology

Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention

Sepideh Mirzaei et al.

Summary: This review highlights the role of epigenetic alterations in the development of prostate cancer, specifically focusing on lncRNAs. Aberrant expression of lncRNAs in prostate cancer is well-documented, affecting various molecular pathways and regulating tumor progression. Additionally, lncRNAs play a role in radio-resistance, chemo-resistance, and immune evasion of prostate cancer, making them potential targets for therapeutic interventions.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Review Biochemistry & Molecular Biology

Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance

Joshua Altschuler et al.

Summary: Prostate cancer mortality poses a significant public health challenge, with therapeutic resistance being a complex issue involving various biological mechanisms. Understanding the mechanisms of resistance is crucial for improving therapeutic outcomes and developing predictive biomarkers. Epithelial-to-mesenchymal transition, mesenchymal-to-epithelial transition, and long non-coding RNAs play important roles in therapeutic resistance and cancer progression.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Cell Biology

Role of noncoding RNA in drug resistance of prostate cancer

Lifeng Ding et al.

Summary: Prostate cancer is a common form of cancer worldwide, and noncoding RNAs play important roles in drug resistance in this disease. Noncoding RNAs, such as miRNAs, lncRNAs, and circRNAs, participate in cellular processes and diseases, and have potential therapeutic applications in prostate cancer.

CELL DEATH & DISEASE (2021)

Article Biotechnology & Applied Microbiology

LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SNDI Axis

Wei Chen et al.

ONCOTARGETS AND THERAPY (2020)

Article Biochemistry & Molecular Biology

Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine

Simeng Wen et al.

MOLECULAR CANCER (2020)

Article Cell Biology

LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis

Meng Wu et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)

Review Medicine, General & Internal

The Diagnosis and Treatment of Prostate Cancer A Review

Mark S. Litwin et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Article Biochemical Research Methods

Revealing protein-lncRNA interaction

Fabrizio Ferre et al.

BRIEFINGS IN BIOINFORMATICS (2016)

Review Genetics & Heredity

Unique features of long non-coding RNA biogenesis and function

Jeffrey J. Quinn et al.

NATURE REVIEWS GENETICS (2016)

Article Genetics & Heredity

The landscape of long noncoding RNAs in the human transcriptome

Matthew K. Iyer et al.

NATURE GENETICS (2015)

Review Biochemistry & Molecular Biology

Long Noncoding RNAs: A New Regulatory Code in Metabolic Control

Xu-Yun Zhao et al.

TRENDS IN BIOCHEMICAL SCIENCES (2015)

Article Cell Biology

Senescence-associated lncRNAs: senescence-associated long noncoding RNAs

Kotb Abdelmohsen et al.

AGING CELL (2013)

Article Genetics & Heredity

Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters

Tiffany Hung et al.

NATURE GENETICS (2011)

Review Oncology

Prostate Cancer

James Mohler et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2010)